Neurodivergent children experience significantly more punishment, correction, and criticism compared to neurotypical peers. For instance, it is estimated that by age 10, a child with ADHD will hear 20 ...

Although targeted therapies and immunotherapy have improved survival outcomes in many patients with lung cancer, these therapies come at a cost, not only financially but also in terms of cumulative ...

This story is from The Pulse, a weekly health and science podcast. Find it on Apple Podcasts, Spotify, or wherever you get your podcasts. Amie Ward has worked in the hospitality industry for more than ...

As a senior instructor for the National De-escalation Training Center, I train law enforcement officers how to de-escalate situations that have the potential to turn violent. A couple of weeks ago I ...

or on the link below. Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered ...

GRAND RAPIDS, Mich. — Padded mats are being utilized in classrooms across West Michigan as part of a cutting-edge approach to crisis de-escalation. Lauren Raap, an emotional impairment teacher at ...

Many people, within the course of their employment, encounter individuals who potentially pose a threat to themselves or others. This dilemma is faced by security professionals, healthcare ...

In the early 2000s, I was conducting a security assessment at a healthcare facility when I observed a telling moment in the waiting room. A mother, visibly stressed, had just learned from the ...

This federally funded program will promote de-escalation tactics within law enforcement and public safety. The primary goal is to deliver the most advanced de-escalation training curated by research, ...

Seminoma, the commonest type of testicular cancer, has a great treatment success rate, with 3-year progression-free survival (PFS) rates of at least 90%. However, the treatment regimen is intense, ...

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study Immune checkpoint blockers ...